Arlington, MA, United States of America

Michael Kelley


Average Co-Inventor Count = 13.2

ph-index = 5

Forward Citations = 292(Granted Patents)


Company Filing History:


Years Active: 1998-2007

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Innovations of Michael Kelley in Amyloid Peptide Modulation

Introduction

Michael Kelley is a notable inventor based in Arlington, MA (US), recognized for his contributions to the field of pharmaceutical sciences. He holds a total of 7 patents, focusing primarily on compounds that modulate the aggregation of β-amyloid peptides, which are significant in the study of amyloidogenic diseases.

Latest Patents

Kelley’s latest patents include innovative compounds that modulate natural β-amyloid peptide aggregation. These modulators are peptides composed entirely of D-amino acids, typically containing 3-5 D-amino acid residues. The peptides include at least two D-amino acid residues selected from D-leucine, D-phenylalanine, and D-valine. A particularly preferred embodiment of these peptides is a retro-inverso isomer of a β-amyloid peptide, specifically a retro-inverso isomer of Aβ. The invention also encompasses modifications at the amino-terminus and carboxy-terminus, with preferred modifying groups including cyclic, heterocyclic, polycyclic, and branched alkyl groups. Additionally, pharmaceutical compositions and diagnostic methods for treating amyloidogenic diseases using these compounds are disclosed.

Career Highlights

Michael Kelley has made significant strides in his career, particularly through his work at Praecis Pharmaceuticals, Inc. His research has contributed to the understanding and potential treatment of diseases associated with amyloid peptide aggregation.

Collaborations

Kelley has collaborated with esteemed colleagues such as Mark A Findeis and Malcolm L Gefter, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Michael Kelley’s innovative work in the modulation of β-amyloid peptide aggregation showcases his commitment to advancing pharmaceutical science. His patents and collaborations reflect a dedication to addressing critical health challenges associated with amyloidogenic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…